Kopran Limited

NSE KOPRAN.NS

Kopran Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.13

Kopran Limited EPS (Diluted) is USD 0.13 for the year ending March 31, 2024, a 84.34% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Kopran Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.07, a -62.09% change year over year.
Kopran Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.18, a -6.75% change year over year.
Kopran Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.19, a 201.55% change year over year.
Kopran Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.06, a -19.25% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: KOPRAN.NS

Kopran Limited

CEO	Mr. Surendra Shrikrishna Somani B.Com.
IPO Date	July 1, 2002
Location	India
Headquarters	Parijat House
Employees	842
Sector	Health Care
Industries Pharmaceuticals

Description

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.

Key trends

Past 5 years